Clinical trial
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine…
NCT00300573 · Incyte Corporation, Industry · Terminated
Key facts
| NCT number | NCT00300573 |
|---|---|
| Title | Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs |
| Official title | A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimized Background Therapy in HIV-1 Infected Subjects Who Have Failed and/or Harbor HIV With Resistance… |
| Acronym | DECLARE |
| Lead sponsor | Incyte Corporation, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Human Immunodeficiency Virus |
| Intervention type | Drug |
| Interventions | Dexelvucitabine |
| Enrollment | 250 |
| Start date | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Mar 9, 2006 |
| Last update posted | Aug 23, 2018 |
| Countries | Puerto Rico, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: